Related Experiment Videos
Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity
Qing Huai1, Huanchen Wang, Yingjie Sun
1Department of Biochemistry and Biophysics and Lineberger Comprehensive Cancer Center, The University of North Carolina, Chapel Hill, Chapel Hill, NC 27599, USA.
Structure (London, England : 1993)
|July 5, 2003
Summary
Understanding how selective cyclic nucleotide phosphodiesterase (PDE) inhibitors bind is key for drug development. Structural analysis reveals that amino acid properties and binding pocket changes dictate inhibitor selectivity, offering insights into drug design for various diseases.
Area of Science:
- Biochemistry
- Structural Biology
- Pharmacology
Background:
- Selective inhibitors targeting the 11 families of cyclic nucleotide phosphodiesterases (PDEs) are crucial therapeutics for numerous human diseases.
- The precise mechanisms by which these inhibitors achieve selectivity within the conserved PDE catalytic domains remain largely unelucidated.
Purpose of the Study:
- To investigate the structural basis of selective inhibitor binding to cyclic nucleotide phosphodiesterase catalytic domains.
- To elucidate the role of specific amino acid residues and conformational dynamics in determining inhibitor selectivity.
Main Methods:
- X-ray crystallography was employed to determine the structures of the PDE4D2 catalytic domain in complex with rolipram enantiomers.
- Molecular docking simulations were performed to analyze the interaction of sildenafil with the PDE4 catalytic pocket.
Main Results:
- Crystal structures reveal that inhibitor selectivity is influenced by the chemical characteristics of amino acids and subtle conformational alterations within the PDE binding pockets.
- The conformational state of Gln369 in PDE4D2 appears critical for inhibitor recognition.
- A Y329S mutation in PDE7 disrupts hydrogen bonding with rolipram, potentially explaining PDE7's insensitivity to this inhibitor.
Conclusions:
- Inhibitor selectivity for PDEs is governed by specific amino acid compositions and dynamic binding pocket conformations.
- Understanding these structural determinants can guide the rational design of more selective and effective PDE inhibitors for therapeutic applications.